Projecting long-term graft and patient survival after transplantation

Value in Health

Volumn 17, Issue 2, 2014, Pages 254-260

  Levy, Adrian R ^a,b   Briggs, Andrew H ^b,c   Johnston, Karissa ^b   Maclean, J Ross ^d   Yuan, Yong ^d   L'Italien, Gilbert J ^d,e   Kalsekar, Anupama ^d   Schnitzler, Mark A ^f  

^a DALHOUSIE UNIVERSITY   (Canada)

^b ICON PLC   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SAINT LOUIS UNIVERSITY   (United States)

Author keywords

decision model; end stage renal disease; modeling; renal transplant

Indexed keywords

AZATHIOPRINE; BELATACEPT; CYCLOSPORIN; PREDNISONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; UNITED STATES;

DECISION MODEL; END STAGE RENAL DISEASE; MODELING; RENAL TRANSPLANT;

ADULT; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOSPORINE; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MARKOV CHAINS; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS;

EID: 84896366459     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.01.001     Document Type: Article

References (49)

1. U.S. Renal Data System USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2008 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
2. R.A. Wolfe, V.B. Ashby, and E.L. Milford et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant N Engl J Med 341 1999 1725 1730
3. B. Kaplan, and H.U. Meier-Kriesche Renal transplantation: a half century of success and the long road ahead J Am Soc Nephrol 15 2004 3270 3271 (Pubitemid 39578861)
4. Organ Procurement and Transplantation Network. Available at: http://optn.transplant.hrsa.gov/latestData/rptData.asp. [Accessed December 23, 2013].
5. Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors: preliminary results of a European multicentre trial Lancet 2 8289 1982 57 60
6. A randomized clinical trial of cyclosporine in cadaveric renal transplantation N Engl J Med 309 14 1983 809 815
7. B.D. Kahan, P.R. Rajagopalan, and M. Hall Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group Transplantation 67 1999 276 284 (Pubitemid 29066355)
8. J.D. Pirsch, J. Miller, and M.H. Deierhoi et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group Transplantation 63 1997 977 983 (Pubitemid 27173021)
9. F. Vincenti, R. Kirkman, and S. Light et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group N Engl J Med 338 1998 161 165 (Pubitemid 28041863)
10. A.S. MacDonald A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts Transplantation 71 2001 271 280
11. H.W. Sollinger Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group Transplantation 60 1995 225 232
12. B.D. Kahan Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group Lancet 356 2000 194 202 (Pubitemid 30446974)
13. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group Lancet 345 8961 1995 1321 1325
14. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group Transplantation 61 7 1996 1029 1037
15. H.U. Meier-Kriesche, J.D. Schold, and T.R. Srinivas et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era Am J Transplant 4 2004 378 383 (Pubitemid 38282293)
16. S. Hariharan, M.A. McBride, and E.P. Cohen Evolution of endpoints for renal transplant outcome Am J Transplant 3 2003 933 941 (Pubitemid 36917538)
17. M. Salvadori, A. Rosati, and A. Bock et al. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant Transplantation 81 2006 202 206
18. S. Hariharan, M.A. McBride, and W.S. Cherikh et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival Kidney Int 62 2002 311 318 (Pubitemid 34754077)
19. B.L. Kasiske, M.A. Andany, and B. Danielson A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure Am J Kidney Dis 39 2002 762 768 (Pubitemid 34263350)
20. H.U. Meier-Kriesche, R. Baliga, and B. Kaplan Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation Transplantation 75 2003 1291 1295 (Pubitemid 36513036)
21. B.L. Kasiske, J.J. Snyder, and D. Gilbertson et al. Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 2003 178 185 (Pubitemid 36323115)
22. O. Wu, A.R. Levy, and A. Briggs et al. Acute rejection and chronic nephropathy: a systematic review of the literature Transplantation 87 2009 1330 1339
23. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338 (Pubitemid 24013155)
24. M. Gera, J.M. Slezak, and A.D. Rule et al. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate Am J Transplant 7 2007 880 887 (Pubitemid 46481182)
25. J.S. Gill, M. Tonelli, and C.H. Mix et al. The change in allograft function among long-term kidney transplant recipients J Am Soc Nephrol 14 2003 1636 1642 (Pubitemid 36687067)
26. B.L. Kasiske, R.S. Gaston, and S. Gourishankar et al. Long-term deterioration of kidney allograft function Am J Transplant 5 2005 1405 1414 (Pubitemid 40839432)
27. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. 2010. Available from: http://www.kidney org/professionals/kdoqi/guidelines-ckd 2010. [Accessed December 23, 2013].
28. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997-2006 2007 Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation Rockville, MD
29. A.H. Briggs Handling uncertainty in cost-effectiveness models Pharmacoeconomics 17 2000 479 500 (Pubitemid 30398806)
30. M.C. Weinstein, E.L. Toy, and E.A. Sandberg et al. Modeling for health care and other policy decisions: uses, roles, and validity Value Health 4 2001 348 361 (Pubitemid 32946233)
31. F. Vincenti, C.P. Larsen, and J. Albert et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients Am J Transplant 12 2012 210 217
32. C.P. Larsen, J. Grinyo, and J. Medina-Pestana et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies Transplantation 90 2010 1528 1535
33. B. Kaplan, J. Schold, and H.U. Meier-Kriesche Overview of large database analysis in renal transplantation Am J Transplant 3 2003 1052 1056 (Pubitemid 37064543)
34. D.M. Dickinson, M.D. Ellison, and R.L. Webb Data sources and structure Am J Transplant 3 Suppl. 4 2003 13 28 (Pubitemid 36612381)
35. D.M. Dickinson, P.C. Bryant, and M.C. Williams et al. Transplant data: sources, collection, and caveats Am J Transplant 4 Suppl. 9 2004 13 26 (Pubitemid 38858992)
36. R.A. Wolfe, K.P. McCullough, and D.E. Schaubel et al. Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates Am J Transplant 8 2008 997 1011 (Pubitemid 351389067)
37. J. Horsman, W. Furlong, and D. Feeny et al. The Health Utilities Index (HUI): concepts, measurement properties and applications Health Qual Life Outcomes 1 2003 54
38. L. Neri, J. Dukes, and D.C. Brennan et al. Impaired renal function is associated with worse self-reported outcomes after kidney transplantation Qual Life Res 20 2011 1689 1698
39. A.S. Levey, J.P. Bosch, and J.B. Lewis et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
40. E.D. Poggio, X. Wang, and D.M. Weinstein et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients Am J Transplant 6 2006 100 108 (Pubitemid 43382207)
41. Briggs A, Sculpher M, Klaxton K. Making decision models probabilistic. In: Decision Modelling for Health Economic Evaluation. Oxford, UK: Oxford University Press, 2006.
42. K.J. Carroll On the use and utility of the Weibull model in the analysis of survival data Control Clin Trials 24 2003 682 701 (Pubitemid 37518386)
43. Briggs A, Sculpher M, Klaxton K. Key aspects of decision modelling for economic evaluation. In: Decision Modelling for Health Economic Evaluation. Oxford, UK: Oxford University Press, 2006.
44. M.A. Schnitzler, K. Johnston, and D. Axelrod et al. Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality, and healthcare costs Transplantation 91 2011 1347 1356
45. F. Vincenti, B. Charpentier, and Y. Vanrenterghem et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study) Am J Transplant 10 2010 535 546
46. B. Kaplan Belatacept: the promises and challenges of belatacept and costimulatory blockade Am J Transplant 10 2010 441 442
47. S.R. Earnshaw, C.N. Graham, and W.D. Irish et al. Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation J Am Soc Nephrol 19 2008 1807 1816
48. B. O'Brien Economic evaluation of pharmaceuticals Frankenstein's monster or vampire of trials? 34 1996 DS99 108
49. E.H. Cole, O. Johnston, and C.L. Rose et al. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival Clin J Am Soc Nephrol 3 2008 814 821